Crossbow Therapeutics, Inc
Tao Wang currently serves as the Vice President of Product Discovery and Boston Site Head at Crossbow Therapeutics, Inc. since May 2022. Previously, Tao Wang held multiple roles at LinkedUp Bioscience Inc, including Consultant, Co-founder, and Vice President of Antibody Discovery, starting in September 2018. From October 2016 to September 2018, Tao Wang was a Senior Scientist at Merck, and prior to that, worked as a Scientist at Biogen from September 2014 to October 2016. Tao Wang's career began at Adimab, LLC as a Scientist from March 2008 to September 2014, following a Research Assistant position at Dartmouth Medical School from August 2005 to March 2008. Additional early experience includes a role as Senior Research Associate at Abbott Bioresearch Center for a brief period in 2005. Educational qualifications include studies at the University of Massachusetts Amherst and Huazhong Agricultural University.
Crossbow Therapeutics, Inc
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.